DK151631B - Analogifremgangsmaade til fremstilling af 3,8-dialkylxantiner. - Google Patents
Analogifremgangsmaade til fremstilling af 3,8-dialkylxantiner. Download PDFInfo
- Publication number
- DK151631B DK151631B DK168281AA DK168281A DK151631B DK 151631 B DK151631 B DK 151631B DK 168281A A DK168281A A DK 168281AA DK 168281 A DK168281 A DK 168281A DK 151631 B DK151631 B DK 151631B
- Authority
- DK
- Denmark
- Prior art keywords
- ethyl
- butyl
- propyl
- compound
- compounds
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 35
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 9
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims abstract description 8
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims abstract description 8
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims abstract description 8
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims abstract description 8
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims abstract description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims abstract description 6
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 claims abstract description 4
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims abstract description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims abstract description 4
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims abstract description 4
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims abstract description 4
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims abstract description 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- -1 cyclo-2-butyl Chemical group 0.000 claims description 4
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 claims description 4
- 230000018044 dehydration Effects 0.000 claims description 3
- 238000006297 dehydration reaction Methods 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 235000013312 flour Nutrition 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 4
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 22
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 239000013078 crystal Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 229960000278 theophylline Drugs 0.000 description 10
- 239000002904 solvent Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- SHKJXAPOAVPNKW-UHFFFAOYSA-N 6-amino-1-ethyl-5-nitrosopyrimidine-2,4-dione Chemical compound CCN1C(N)=C(N=O)C(=O)NC1=O SHKJXAPOAVPNKW-UHFFFAOYSA-N 0.000 description 5
- KTWOUYVBZDZRNV-UHFFFAOYSA-N 6-amino-1-propylpyrimidine-2,4-dione Chemical compound CCCN1C(N)=CC(=O)NC1=O KTWOUYVBZDZRNV-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 210000003437 trachea Anatomy 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- AHSKLSFFKJHWAI-RGMNGODLSA-N (2s)-2-amino-5-[[amino(dimethylamino)methylidene]amino]pentanoic acid;hydrochloride Chemical compound Cl.CN(C)C(N)=NCCC[C@H](N)C(O)=O AHSKLSFFKJHWAI-RGMNGODLSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- MLIREBYILWEBDM-UHFFFAOYSA-N cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- HEXZSEOAILCDMD-UHFFFAOYSA-N 5,6-diamino-1-ethylpyrimidine-2,4-dione Chemical compound CCN1C(N)=C(N)C(=O)NC1=O HEXZSEOAILCDMD-UHFFFAOYSA-N 0.000 description 2
- YOMSKQSCRYRZDC-UHFFFAOYSA-N 5,6-diamino-1-propylpyrimidine-2,4-dione Chemical compound CCCN1C(N)=C(N)C(=O)NC1=O YOMSKQSCRYRZDC-UHFFFAOYSA-N 0.000 description 2
- PJHVUYYGBOUXNX-UHFFFAOYSA-N 6-amino-5-nitroso-1-propylpyrimidine-2,4-dione Chemical compound CCCN1C(N)=C(N=O)C(=O)NC1=O PJHVUYYGBOUXNX-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 229920000945 Amylopectin Polymers 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000003182 bronchodilatating effect Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- KPCXHYGABMLZIK-UHFFFAOYSA-N 3,8-dipropyl-7h-purine-2,6-dione Chemical compound CCCN1C(=O)NC(=O)C2=C1N=C(CCC)N2 KPCXHYGABMLZIK-UHFFFAOYSA-N 0.000 description 1
- QPHOMKKIIXKEFJ-UHFFFAOYSA-N 3-(2,2-dimethylpropyl)-8-ethyl-7h-purine-2,6-dione Chemical compound CC(C)(C)CN1C(=O)NC(=O)C2=C1N=C(CC)N2 QPHOMKKIIXKEFJ-UHFFFAOYSA-N 0.000 description 1
- HNCVLKPKADKQRS-UHFFFAOYSA-N 3-(cyclohexylmethyl)-8-ethyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)C=2NC(CC)=NC=2N1CC1CCCCC1 HNCVLKPKADKQRS-UHFFFAOYSA-N 0.000 description 1
- QGQYTYQGUZHPRN-UHFFFAOYSA-N 3-butyl-8-ethyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)N(CCCC)C2=C1NC(CC)=N2 QGQYTYQGUZHPRN-UHFFFAOYSA-N 0.000 description 1
- SLCXXNSWUYKYPG-UHFFFAOYSA-N 3-cyclopropyl-8-propyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)C=2NC(CCC)=NC=2N1C1CC1 SLCXXNSWUYKYPG-UHFFFAOYSA-N 0.000 description 1
- CLRHVOHIFNLQBD-UHFFFAOYSA-N 3-ethyl-8-methyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)N(CC)C2=C1NC(C)=N2 CLRHVOHIFNLQBD-UHFFFAOYSA-N 0.000 description 1
- WSASYFRNDGIHPI-UHFFFAOYSA-N 3-ethyl-8-propan-2-yl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)N(CC)C2=C1NC(C(C)C)=N2 WSASYFRNDGIHPI-UHFFFAOYSA-N 0.000 description 1
- JFUQVWKKZAYRSJ-UHFFFAOYSA-N 3-ethyl-8-propyl-7h-purine-2,6-dione Chemical compound CCN1C(=O)NC(=O)C2=C1N=C(CCC)N2 JFUQVWKKZAYRSJ-UHFFFAOYSA-N 0.000 description 1
- QHEMDIZENXAVRQ-UHFFFAOYSA-N 6-amino-1-ethylpyrimidine-2,4-dione Chemical compound CCN1C(N)=CC(=O)NC1=O QHEMDIZENXAVRQ-UHFFFAOYSA-N 0.000 description 1
- PDKNBSLTBPMRHQ-UHFFFAOYSA-N 8-(2-methylpropyl)-3-propyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)N(CCC)C2=C1NC(CC(C)C)=N2 PDKNBSLTBPMRHQ-UHFFFAOYSA-N 0.000 description 1
- FKEKRSDFADVUIR-UHFFFAOYSA-N 8-butyl-3-ethyl-7h-purine-2,6-dione Chemical compound CCN1C(=O)NC(=O)C2=C1N=C(CCCC)N2 FKEKRSDFADVUIR-UHFFFAOYSA-N 0.000 description 1
- PNQAEUAKVKPMTF-UHFFFAOYSA-N 8-butyl-3-propyl-7h-purine-2,6-dione Chemical compound CCCN1C(=O)NC(=O)C2=C1N=C(CCCC)N2 PNQAEUAKVKPMTF-UHFFFAOYSA-N 0.000 description 1
- PMQWRMJBBJNEMM-UHFFFAOYSA-N 8-cyclobutyl-3-propyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)NC(=O)N(CCC)C=2N=C1C1CCC1 PMQWRMJBBJNEMM-UHFFFAOYSA-N 0.000 description 1
- GGOSLMWKWVWOCQ-UHFFFAOYSA-N 8-cyclopropyl-3-propyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)NC(=O)N(CCC)C=2N=C1C1CC1 GGOSLMWKWVWOCQ-UHFFFAOYSA-N 0.000 description 1
- MJZJLHAIWFTNNB-UHFFFAOYSA-N 8-ethyl-3-(2-methylpropyl)-7h-purine-2,6-dione Chemical compound CC(C)CN1C(=O)NC(=O)C2=C1N=C(CC)N2 MJZJLHAIWFTNNB-UHFFFAOYSA-N 0.000 description 1
- DYDNLUOQZZAUEZ-UHFFFAOYSA-N 8-ethyl-3-(3-methylbutyl)-7h-purine-2,6-dione Chemical compound CC(C)CCN1C(=O)NC(=O)C2=C1N=C(CC)N2 DYDNLUOQZZAUEZ-UHFFFAOYSA-N 0.000 description 1
- MXNWQDSTCBTICY-UHFFFAOYSA-N 8-ethyl-3-pentyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)N(CCCCC)C2=C1NC(CC)=N2 MXNWQDSTCBTICY-UHFFFAOYSA-N 0.000 description 1
- CESVXSGKVYVAIY-UHFFFAOYSA-N 8-ethyl-3-propyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)N(CCC)C2=C1NC(CC)=N2 CESVXSGKVYVAIY-UHFFFAOYSA-N 0.000 description 1
- CNVJBOYEHORNLI-UHFFFAOYSA-N 8-propan-2-yl-3-propyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)N(CCC)C2=C1NC(C(C)C)=N2 CNVJBOYEHORNLI-UHFFFAOYSA-N 0.000 description 1
- HWYGLJMXISRPOR-UHFFFAOYSA-N 8-tert-butyl-3-propyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)N(CCC)C2=C1NC(C(C)(C)C)=N2 HWYGLJMXISRPOR-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102100031667 Cell adhesion molecule-related/down-regulated by oncogenes Human genes 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- RYECOJGRJDOGPP-UHFFFAOYSA-N Ethylurea Chemical compound CCNC(N)=O RYECOJGRJDOGPP-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920003266 Leaf® Polymers 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 229910018954 NaNH2 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 101150057249 iHog gene Proteins 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- ZQZJKHIIQFPZCS-UHFFFAOYSA-N propylurea Chemical compound CCCNC(N)=O ZQZJKHIIQFPZCS-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE8002910 | 1980-04-18 | ||
SE8002910A SE8002910L (sv) | 1980-04-18 | 1980-04-18 | 3,8-dialkylxantiner, forfarande for deras framstellning, beredning och metoder for behandling av kronisk obstruktiv luftvegssjukdom och kardiovaskulera sjukdomar |
Publications (2)
Publication Number | Publication Date |
---|---|
DK168281A DK168281A (da) | 1981-10-19 |
DK151631B true DK151631B (da) | 1987-12-21 |
Family
ID=20340763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK168281AA DK151631B (da) | 1980-04-18 | 1981-04-14 | Analogifremgangsmaade til fremstilling af 3,8-dialkylxantiner. |
Country Status (21)
Country | Link |
---|---|
US (1) | US4546182A (fr) |
EP (1) | EP0038784B1 (fr) |
JP (1) | JPS56166191A (fr) |
AT (1) | ATE10099T1 (fr) |
AU (1) | AU543122B2 (fr) |
CA (1) | CA1156229A (fr) |
DD (1) | DD158400A5 (fr) |
DE (1) | DE3166893D1 (fr) |
DK (1) | DK151631B (fr) |
ES (1) | ES8203088A1 (fr) |
FI (1) | FI69465C (fr) |
GR (1) | GR82347B (fr) |
HU (1) | HU185254B (fr) |
IE (1) | IE51106B1 (fr) |
NO (1) | NO811161L (fr) |
NZ (1) | NZ196829A (fr) |
PH (1) | PH16264A (fr) |
PL (1) | PL134762B1 (fr) |
PT (1) | PT72881B (fr) |
SE (1) | SE8002910L (fr) |
ZA (1) | ZA811729B (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE7810947L (sv) * | 1978-10-20 | 1980-04-21 | Draco Ab | 3-alkylxanthines |
US4710503A (en) * | 1985-02-07 | 1987-12-01 | Euroceltique S.A. | 6-thioxanthine derivatives |
GB8618931D0 (en) * | 1986-08-02 | 1986-09-10 | Euro Celtique Sa | 6-thioxanthines |
US5298508A (en) * | 1988-07-19 | 1994-03-29 | The United States Of America As Represented By The Department Of Health And Human Services | Irreversible inhibitors of adenosine receptors |
JP2843634B2 (ja) * | 1989-03-06 | 1999-01-06 | 協和醗酵工業株式会社 | キサンチン誘導体 |
IT1229195B (it) * | 1989-03-10 | 1991-07-25 | Poli Ind Chimica Spa | Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche. |
WO1990012797A1 (fr) * | 1989-04-19 | 1990-11-01 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Derives de xanthene contenant du soufre comme antagonistes d'adenosine |
CA2030112A1 (fr) * | 1989-11-24 | 1991-05-25 | Yasuo Ito | Compose de xanthine, methode de preparation et composition pharmaceutique contenant ledit compose |
US5366977A (en) * | 1992-09-29 | 1994-11-22 | The United States Of America, As Represented By The Department Of Health And Human Services | Method of treating cystic fibrosis using 8-cyclopentyl-1,3-dipropylxanthine or xanthine amino congeners |
DE4311538C1 (de) * | 1993-04-07 | 1994-10-06 | Boehringer Ingelheim Kg | Verfahren zur Herstellung von 1,3-Dimethyl-4,5-diaminouracil |
WO1994025462A1 (fr) * | 1993-05-03 | 1994-11-10 | The United States Of America, Represented By The | Derives de 1,3,7-trialkyl-xanthine substitues en position 8 utiles comme antagonistes de recepteurs d'adenosine a2 a selectivite |
US6316423B1 (en) | 1996-04-10 | 2001-11-13 | The United States Of America As Represented By The Departmant Of Health And Human Services | Method of treating ischemic, hypoxic and anoxic brain damage |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4089959A (en) * | 1976-03-31 | 1978-05-16 | Cooper Laboratories, Inc. | Long-acting xanthine bronchodilators and antiallergy agents |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS53890B2 (fr) * | 1972-04-22 | 1978-01-12 | ||
CA1077932A (fr) * | 1976-03-31 | 1980-05-20 | Berlex Laboratories, Inc. | Composes de la xanthine pour le traitement des bronchospasmes et des affections allergiques |
SE416810C (sv) * | 1977-10-14 | 1982-07-19 | Draco Ab | Forfarande for framstellning av xantinderivat med antiallergisk aktivitet |
SE7810947L (sv) * | 1978-10-20 | 1980-04-21 | Draco Ab | 3-alkylxanthines |
SE7810946L (sv) * | 1978-10-20 | 1980-04-21 | Draco Ab | Metod att behandla kronisk obstruktiv luftvegssjukdom |
-
1980
- 1980-04-18 SE SE8002910A patent/SE8002910L/xx not_active Application Discontinuation
-
1981
- 1981-03-09 EP EP81850039A patent/EP0038784B1/fr not_active Expired
- 1981-03-09 AT AT81850039T patent/ATE10099T1/de not_active IP Right Cessation
- 1981-03-09 DE DE8181850039T patent/DE3166893D1/de not_active Expired
- 1981-03-16 ZA ZA00811729A patent/ZA811729B/xx unknown
- 1981-03-17 CA CA000373230A patent/CA1156229A/fr not_active Expired
- 1981-04-01 PH PH25455A patent/PH16264A/en unknown
- 1981-04-03 NO NO811161A patent/NO811161L/no unknown
- 1981-04-08 IE IE769/81A patent/IE51106B1/en unknown
- 1981-04-14 DD DD81229229A patent/DD158400A5/de unknown
- 1981-04-14 DK DK168281AA patent/DK151631B/da active IP Right Grant
- 1981-04-15 ES ES501400A patent/ES8203088A1/es not_active Expired
- 1981-04-15 NZ NZ196829A patent/NZ196829A/en unknown
- 1981-04-15 AU AU69555/81A patent/AU543122B2/en not_active Ceased
- 1981-04-15 GR GR64702A patent/GR82347B/el unknown
- 1981-04-16 PT PT72881A patent/PT72881B/pt unknown
- 1981-04-16 FI FI811212A patent/FI69465C/fi not_active IP Right Cessation
- 1981-04-17 JP JP5724181A patent/JPS56166191A/ja active Pending
- 1981-04-17 PL PL1981230737A patent/PL134762B1/pl unknown
- 1981-04-17 HU HU811020A patent/HU185254B/hu unknown
-
1983
- 1983-08-16 US US06/523,731 patent/US4546182A/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4089959A (en) * | 1976-03-31 | 1978-05-16 | Cooper Laboratories, Inc. | Long-acting xanthine bronchodilators and antiallergy agents |
Also Published As
Publication number | Publication date |
---|---|
NO811161L (no) | 1981-10-19 |
AU6955581A (en) | 1981-10-22 |
PL134762B1 (en) | 1985-09-30 |
PL230737A1 (fr) | 1982-03-29 |
JPS56166191A (en) | 1981-12-21 |
ES501400A0 (es) | 1982-02-16 |
NZ196829A (en) | 1984-12-14 |
DE3166893D1 (en) | 1984-12-06 |
PT72881A (en) | 1981-05-01 |
HU185254B (en) | 1984-12-28 |
IE51106B1 (en) | 1986-10-01 |
EP0038784B1 (fr) | 1984-10-31 |
DD158400A5 (de) | 1983-01-12 |
PT72881B (en) | 1983-03-29 |
EP0038784A2 (fr) | 1981-10-28 |
ES8203088A1 (es) | 1982-02-16 |
GR82347B (fr) | 1984-12-13 |
AU543122B2 (en) | 1985-04-04 |
PH16264A (en) | 1983-08-23 |
SE8002910L (sv) | 1981-10-19 |
FI811212L (fi) | 1981-10-19 |
EP0038784A3 (en) | 1982-01-20 |
FI69465C (fi) | 1986-02-10 |
DK168281A (da) | 1981-10-19 |
CA1156229A (fr) | 1983-11-01 |
ZA811729B (en) | 1982-04-28 |
FI69465B (fi) | 1985-10-31 |
US4546182A (en) | 1985-10-08 |
IE810796L (en) | 1981-10-18 |
ATE10099T1 (de) | 1984-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0011609B1 (fr) | Dérivés de xanthine et préparation pharmaceutique les contenant pour utilisation dans le traitement de maladies chroniques d'obstruction des voies respiratoires et de maladies cardiaques | |
EP0010531B1 (fr) | Alcoyl-3-xanthines, procédés pour leur préparation et compositions utilisables dans le traitement de maladies chroniques des voies respiratoires et de maladies cardiaques | |
EP0435811B1 (fr) | Dérivés de xanthine | |
FI66383C (fi) | Foerfarande foer framstaellning av farmakologiskt aktiva xantinderivat | |
DK151631B (da) | Analogifremgangsmaade til fremstilling af 3,8-dialkylxantiner. | |
DK161965B (da) | 6-thioxanthiner og salte deraf samt deres fremstilling og anvendelse | |
JPS61178966A (ja) | 新規1−(2−ピリジル)ピペラジン化合物、その製造方法及びその医薬への用途 | |
JPH0222075B2 (fr) | ||
WO1999062905A1 (fr) | Derives de 8-phenylxanthine et leur utilisation en tant qu'inhibiteurs de phosphodiesterase | |
IE780310L (en) | Heterocyclopyrimidines | |
JPH05262770A (ja) | 化学的製法 | |
KR830001654B1 (ko) | 만성장애 기도증과 심장병 치료를 위한 3-알킬 크산틴의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PHB | Application deemed withdrawn due to non-payment or other reasons | ||
B1 | Patent granted (law 1993) |